glp 1 approved for cardiovascular disease GLP-1 Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 Receptor Agonists in Heart
Description
Dry mouth is a documented side effect reported by some patients taking GLP-1 receptor agonists like semaglutide
Purpose of Review Obesity pharmacotherapy has become increasingly relevant in older adults due to challenges in lifestyle modification and the burden of non-communicable diseases
Learn about their unique characteristics, benefits, side effec...
Such improvements are crucial in mitigating the risk of obesity-related comorbidities, notably cardiovascular diseases and type 2 diabetes, which stand as leading contributors to global morbidity and mortality
Safe, certified, and effective weight loss.
The approval pertains to the GLP-1 drug dubbed Xianweiying also known as ecnoglutide which Pfizer has just acquired in a billion-dollar deal.
